利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.015 秒)

    Monoclonal antibodies to mesenchymal stem cells
    2.
    发明授权
    Monoclonal antibodies to mesenchymal stem cells 有权
    间充质干细胞的单克隆抗体

    公开(公告)号：US07476540B2

    公开(公告)日：2009-01-13

    申请号：US11329523

    申请日：2006-01-10

    申请人： Yeong-Wook Song ,  Hyun-Jung Yoo ,  Sung-Soo Yoon ,  Seonyang Park ,  Weon-Seo Park ,  Dong-Jo Kim ,  Eun-Bong Lee

    发明人： Yeong-Wook Song ,  Hyun-Jung Yoo ,  Sung-Soo Yoon ,  Seonyang Park ,  Weon-Seo Park ,  Dong-Jo Kim ,  Eun-Bong Lee

    IPC分类号： C12N5/00 ,  C07K16/00

    CPC分类号： G01N33/56966 ,  C07K16/28

    摘要： The present invention relates to monoclonal antibodies specifically binding to a membrane antigen of human mesenchymal stem cells, hybridoma cell lines producing the same, and methods for identifying or isolating human mesenchymal stem cells using the same. The monoclonal antibodies of this invention exhibit excellent specificity to human mesenchymal stem cells, inter alia, bone marrow-derived human mesenchymal stem cells, so that it allows for the identification and isolation of human mesenchymal stem cells with much higher specificity.

    摘要翻译： 本发明涉及特异性结合人间充质干细胞的膜抗原的单克隆抗体，产生其的杂交瘤细胞系以及使用其的鉴定或分离人间充质干细胞的方法。 本发明的单克隆抗体对人类间充质干细胞，特别是对骨髓来源的人间充质干细胞表现出极好的特异性，从而允许以更高的特异性鉴定和分离人间充质干细胞。

    Antibodies to ip-10 for treating bone diseases with bone destruction
    6.
    发明申请
    Antibodies to ip-10 for treating bone diseases with bone destruction 有权
    ip-10的抗体用于骨破坏治疗骨病

    公开(公告)号：US20100021463A1

    公开(公告)日：2010-01-28

    申请号：US12311786

    申请日：2007-08-17

    申请人： Young Wook Song ,  Zang Hee Lee ,  Eun Bong Lee ,  Eun Young Lee

    发明人： Young Wook Song ,  Zang Hee Lee ,  Eun Bong Lee ,  Eun Young Lee

    IPC分类号： A61K39/395 ,  G01N33/566 ,  A61P19/10 ,  A61P19/02 ,  A61P19/08

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/76

    摘要： The present invention is directed to providing the IP-10 protein (interferon-γ-inducible protein 10) as a novel therapeutic target relating to the etiology of bone diseases with bone destruction associated with RNAKL expression and osteoclast formation. More specifically, the present invention relates to (i) a pharmaceutical composition for preventing or treating a disease or disorder associated with the expression of RANKL (receptor activator of NF-κB ligand), (ii) a method for inhibiting the expression of RANKL and (iii) a method for screening an antibody drug candidate to inhibit the expression of RANKL.

    摘要翻译： 本发明旨在提供IP-10蛋白（干扰素-γ-诱导蛋白10）作为与RNAK1表达和破骨细胞形成相关的骨破坏的骨疾病病因的新型治疗靶标。 更具体地，本发明涉及（i）用于预防或治疗与RANKL（NF-κB配体的受体激活剂）的表达相关的疾病或病症的药物组合物，（ii）抑制RANKL表达的方法和 （iii）筛选抗体药物候选物以抑制RANKL表达的方法。

    Antibodies to IP-10 for treating bone diseases with bone destruction
    7.
    发明授权
    Antibodies to IP-10 for treating bone diseases with bone destruction 有权
    用于治疗骨破坏骨质疾病的IP-10抗体

    公开(公告)号：US08178100B2

    公开(公告)日：2012-05-15

    申请号：US12311786

    申请日：2007-08-17

    申请人： Young Wook Song ,  Zang Hee Lee ,  Eun Bong Lee ,  Eun Young Lee

    发明人： Young Wook Song ,  Zang Hee Lee ,  Eun Bong Lee ,  Eun Young Lee

    IPC分类号： A61K39/395 ,  C07K16/24

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/76

    摘要： The present invention is directed to providing the IP-10 protein (interferon-γ-inducible protein 10) as a novel therapeutic target relating to the etiology of bone diseases with bone destruction associated with RNAKL expression and osteoclast formation. More specifically, the present invention relates to (i) a pharmaceutical composition for preventing or treating a disease or disorder associated with the expression of RANKL (receptor activator of NF-κB ligand), (ii) a method for inhibiting the expression of RANKL and (iii) a method for screening an antibody drug candidate to inhibit the expression of RANKL.

    摘要翻译： 本发明旨在提供IP-10蛋白（干扰素-γ诱导蛋白10）作为与RNAKL表达和破骨细胞形成相关的骨破坏的骨疾病的病因有关的新型治疗靶点。 更具体地，本发明涉及（i）用于预防或治疗与RANKL（NF-κB配体的受体激活剂）的表达相关的疾病或病症的药物组合物，（ii）抑制 RANKL和（iii）筛选抗体药物候选物以抑制RANKL表达的方法。